Skip to main content
Erschienen in: Familial Cancer 1/2012

01.03.2012 | Original Article

Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma

verfasst von: X.-P. Qi, R.-B. Ying, J.-M. Ma, W.-T. Liu, Z.-F. Du, J. Fei, C.-P. Yang, Q.-Z. Song, H.-Y. Jin, Z.-G. Chen, J.-S. Han, J.-Q. Wang, X.-L. Chen, Y. Zhao, J.-J. Lu, X.-N. Zhang

Erschienen in: Familial Cancer | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

We report a Chinese pedigree with familial medullary thyroid carcinoma. Direct sequencing of the entire coding sequences of Rearranged during Transfection (RET) identified a recurrent c.T1852A (p.C618S) mutation in 13 of 23 members. The polymorphisms c.A135G (p.A45A), c.A1296G (p.A432A), c.T2307G (p.L769L) and IVS19 + 15T > C were also found in 13 carriers, and c.G2073A (p.G691S) was found in 1 carrier. Of the 13 carriers, seven (mean age: 42.6 years, range: 27–64) presented MTC as the isolated clinical phenotype, with elevated basal serum calcitonin (average: 1077.9 ng/L, range: 504–2,652) and a mean diameter of thyroid nodules of 2.97 cm (range: 1.6–4.3); they underwent a total thyroidectomy with modified bilateral/unilateral neck dissection and/or level VI lymph node dissection. The other 6 carriers did not accept surgery (4 rejected, 2 awaited). These were 2 older patients (63 and 32 years) with elevated calcitonin (1359 and 41.4 ng/L) and multi-centric hypoechoic nodules (1.5 and 0.6 cm) with calcifications in both/left thyroid lobes; and Doppler ultrasound showed normal bilateral thyroids in 4 younger carriers (median age: 8.3 years, range: 4–12) but with increased calcitonin (average: 9.7 ng/L, range: 7.87–12.2) in 3 of them. The phenotype here is consistent with the clinical symptoms reported worldwide. We recommend that screening of hotspot regions of RET should be preferentially carried out, while whole-exon sequencing should be performed when clinical signs fail to reveal hotspot mutations or different phenotype discrepancies. Moreover, we strongly suggest prophylactic thyroidectomy should be performed before age 5 in carriers with p.C618S to prevent the occurrence and metastasis of MTC.
Literatur
1.
Zurück zum Zitat Kloos RT, Eng C et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612PubMedCrossRef Kloos RT, Eng C et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612PubMedCrossRef
2.
Zurück zum Zitat Qi XP, Ma JM et al (2011) RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family. Plos One 6:e20353PubMedCrossRef Qi XP, Ma JM et al (2011) RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family. Plos One 6:e20353PubMedCrossRef
3.
Zurück zum Zitat Eng C, Clayton D et al (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575–1579PubMedCrossRef Eng C, Clayton D et al (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575–1579PubMedCrossRef
4.
Zurück zum Zitat Raue F, Frank-Raue K (2010) Update multiple endocrine neoplasia type 2. Fam Cancer 9:449–457PubMedCrossRef Raue F, Frank-Raue K (2010) Update multiple endocrine neoplasia type 2. Fam Cancer 9:449–457PubMedCrossRef
5.
Zurück zum Zitat Frank-Raue K, Rondot S, Raue F (2010) Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC. Mol Cell Endocrinol 322:2–7PubMedCrossRef Frank-Raue K, Rondot S, Raue F (2010) Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC. Mol Cell Endocrinol 322:2–7PubMedCrossRef
6.
Zurück zum Zitat Pierotti MA, Santoro M et al (1992) Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci 89:1616–1620PubMedCrossRef Pierotti MA, Santoro M et al (1992) Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci 89:1616–1620PubMedCrossRef
7.
Zurück zum Zitat Donis-Keller H, Dou S et al (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851–856PubMedCrossRef Donis-Keller H, Dou S et al (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851–856PubMedCrossRef
8.
Zurück zum Zitat Eng C, Mulligan L (1997) Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum Mutat 9:97–109PubMedCrossRef Eng C, Mulligan L (1997) Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum Mutat 9:97–109PubMedCrossRef
9.
Zurück zum Zitat Jung J, Uchino S et al (2010) A Korean family of familial medullary thyroid cancer with Cys618Ser RET germline mutation. J Korean Med Sci 25:226–229PubMedCrossRef Jung J, Uchino S et al (2010) A Korean family of familial medullary thyroid cancer with Cys618Ser RET germline mutation. J Korean Med Sci 25:226–229PubMedCrossRef
10.
Zurück zum Zitat Hofstra RM, Fattoruso O et al (1997) A novel point mutation in the intracellular domain of the RET protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82:4176–4178PubMedCrossRef Hofstra RM, Fattoruso O et al (1997) A novel point mutation in the intracellular domain of the RET protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82:4176–4178PubMedCrossRef
11.
Zurück zum Zitat Dabir T, Hunter SJ et al (2006) The RET mutation E768D confers a late-onset familial medullary thyroid carcinoma—only phenotype with incomplete penetrance: implications for screening and management of carrier status. Fam Cancer 5:201–204PubMedCrossRef Dabir T, Hunter SJ et al (2006) The RET mutation E768D confers a late-onset familial medullary thyroid carcinoma—only phenotype with incomplete penetrance: implications for screening and management of carrier status. Fam Cancer 5:201–204PubMedCrossRef
12.
Zurück zum Zitat Kameyama K, Okinaga H, Takami H (2004) RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan. Biomed Pharmacother 58:345–347PubMedCrossRef Kameyama K, Okinaga H, Takami H (2004) RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan. Biomed Pharmacother 58:345–347PubMedCrossRef
13.
Zurück zum Zitat Da Silva AM, Maciel RM et al (2003) A novel germ-line point mutation in RET exon 8 (Gly533Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 88:5438–5443PubMedCrossRef Da Silva AM, Maciel RM et al (2003) A novel germ-line point mutation in RET exon 8 (Gly533Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 88:5438–5443PubMedCrossRef
14.
Zurück zum Zitat Pinna G, Orgiana G et al (2007) RET proto-oncogene in Sardinia: V804 M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype. Thyroid 17:101–104PubMedCrossRef Pinna G, Orgiana G et al (2007) RET proto-oncogene in Sardinia: V804 M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype. Thyroid 17:101–104PubMedCrossRef
15.
Zurück zum Zitat Castellone MD, Verrienti A et al (2010) A novel de novo germ-line V292 M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization. Clin Endocrinol (Oxf) 73:529–534 Castellone MD, Verrienti A et al (2010) A novel de novo germ-line V292 M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization. Clin Endocrinol (Oxf) 73:529–534
16.
Zurück zum Zitat Ceccherini I, Hofstra RM et al (1994) DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene 9:3025–3029PubMed Ceccherini I, Hofstra RM et al (1994) DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret proto-oncogene. Oncogene 9:3025–3029PubMed
17.
Zurück zum Zitat Elisei R, Cosci B et al (2004) RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 89:3579–3584PubMedCrossRef Elisei R, Cosci B et al (2004) RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 89:3579–3584PubMedCrossRef
18.
Zurück zum Zitat Borrego S, Saez ME et al (1999) Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 36:771–774PubMed Borrego S, Saez ME et al (1999) Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 36:771–774PubMed
19.
Zurück zum Zitat Lesueur F, Corbex M et al (2002) Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma. J Med Genet 39:260–265PubMedCrossRef Lesueur F, Corbex M et al (2002) Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma. J Med Genet 39:260–265PubMedCrossRef
20.
Zurück zum Zitat Robledo M, Gil L et al (2003) Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res 63:1814–1817PubMed Robledo M, Gil L et al (2003) Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res 63:1814–1817PubMed
21.
Zurück zum Zitat Baumgartner-Parzer SM, Lang R et al (2005) Polymorphisms in Exon 13 and Intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab 90:6232–6236PubMedCrossRef Baumgartner-Parzer SM, Lang R et al (2005) Polymorphisms in Exon 13 and Intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab 90:6232–6236PubMedCrossRef
22.
Zurück zum Zitat Morrison PJ, Atkinson AB (2009) Genetic aspects of familial thyroid cancer. Oncologist 14:571–577PubMedCrossRef Morrison PJ, Atkinson AB (2009) Genetic aspects of familial thyroid cancer. Oncologist 14:571–577PubMedCrossRef
23.
Zurück zum Zitat Romei C, Cosci B et al (2011) RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin Endocrinol (Oxf) 74:241–247CrossRef Romei C, Cosci B et al (2011) RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin Endocrinol (Oxf) 74:241–247CrossRef
Metadaten
Titel
Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma
verfasst von
X.-P. Qi
R.-B. Ying
J.-M. Ma
W.-T. Liu
Z.-F. Du
J. Fei
C.-P. Yang
Q.-Z. Song
H.-Y. Jin
Z.-G. Chen
J.-S. Han
J.-Q. Wang
X.-L. Chen
Y. Zhao
J.-J. Lu
X.-N. Zhang
Publikationsdatum
01.03.2012
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 1/2012
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-011-9487-1

Weitere Artikel der Ausgabe 1/2012

Familial Cancer 1/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.